EDWARDS LIFESCIENCES CORPORATION (EW) FY2025 Annual P&L / Income Statement

EDWARDS LIFESCIENCES CORPORATION (EW) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

6,067,600,000 US dollars

Cost of sales

1,334,200,000 US dollars

Gross profit

4,733,400,000 US dollars

Operating costs, net of other operating income (calculated)

3,469,200,000 US dollars

Operating income

1,264,200,000 US dollars

Other income (expense), net (calculated)

8,700,000 US dollars

Income from continuing operations before provision for income taxes

1,272,900,000 US dollars

Provision for income taxes (Note 19)

216,900,000 US dollars

Net income

1,069,400,000 US dollars

Transcatheter Aortic Valve Replacement

4,487,700,000 US dollars

Transcatheter Mitral and Tricuspid Therapies

550,600,000 US dollars

Surgical Structural Heart

1,029,300,000 US dollars

Selling, general, and administrative expenses

2,085,200,000 US dollars

Research and development expenses

1,079,200,000 US dollars

Intellectual property agreement and certain litigation expenses (Note 3)

325,400,000 US dollars

Change in fair value of contingent consideration liabilities (Note 13)

negative 12,500,000 US dollars

Restructuring charges, separation costs, and other (Note 4)

19,100,000 US dollars

Intangible assets impairment charges

40,000,000 US dollars

Other operating income

negative 67,200,000 US dollars

Income from discontinued operations, net of tax

13,400,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
• Of which attributable to EDWARDS LIFESCIENCES CORPORATION: $1.07 B; to noncontrolling interests: −$4.10 M.